Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tharimmune, Inc. - Common Stock
(NQ:
THAR
)
2.860
-0.100 (-3.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
26,008
Open
3.000
Bid (Size)
2.840 (2)
Ask (Size)
3.100 (7)
Prev. Close
2.960
Today's Range
2.850 - 3.000
52wk Range
2.540 - 142.50
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
THAR Stock Earnings: Tharimmune Reported Results for Q2 2024
August 12, 2024
Tharimmune just reported results for the second quarter of 2024.
Via
InvestorPlace
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
July 22, 2024
Via
ACCESSWIRE
Performance
YTD
-62.24%
-62.24%
1 Month
-7.14%
-7.14%
3 Month
-37.42%
-37.42%
6 Month
-49.43%
-49.43%
1 Year
-96.53%
-96.53%
More News
Read More
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
July 17, 2024
Via
ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
July 16, 2024
Via
ACCESSWIRE
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
July 10, 2024
Via
ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
June 20, 2024
Via
ACCESSWIRE
Why Tharimmune (THAR) Shares Are Moving
May 22, 2024
Via
Benzinga
THAR Stock Earnings: Tharimmune Reported Results for Q4 2023
May 09, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 17, 2024
Via
Benzinga
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
June 17, 2024
Via
ACCESSWIRE
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 10, 2024
Via
Benzinga
Why Tharimmune (THAR) Shares Are Getting Hammered
June 10, 2024
Via
Benzinga
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
June 10, 2024
Via
ACCESSWIRE
Tharimmune to Present at 2024 BIO International Convention
May 29, 2024
Via
ACCESSWIRE
Why Is Verastem (VSTM) Stock Down 62% Today?
May 24, 2024
Via
InvestorPlace
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
May 24, 2024
Via
InvestorPlace
Why Is Tharimmune (THAR) Stock Moving Today?
May 24, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 24, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Tharimmune Announces 1-for-15 Reverse Stock Split
May 22, 2024
Via
ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
May 16, 2024
Via
Investor Brand Network
Tharimmune To Participate in Two Upcoming Investor Conferences in May
April 30, 2024
Via
ACCESSWIRE
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
April 23, 2024
Via
ACCESSWIRE
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
April 15, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.